p53 regulation Teamwork between RING domains of Mdm2 and MdmX

被引:40
作者
Wang, Xinjiang [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
关键词
p53; Mdm2; MdmX; Mdm2/MdmX; MDM4; RING domains; protein stability; ubiquitination; lethality; knockout; knockin; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; UBIQUITIN LIGASE; EMBRYONIC LETHALITY; IN-VIVO; ANTAGONISTIC PLEIOTROPY; MDM2-DEFICIENT MICE; CELL SENESCENCE; QUIESCENT CELLS; ACTIVATES P53;
D O I
10.4161/cc.10.24.18662
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
p53 is a major tumor suppressor frequently inactivated through direct gene mutation and alternative mechanisms including overexpression of Mdm2 and MdmX. Both Mdm2 and MdmX are essential for negative regulation of p53 in vivo in a mutually dependent manner. The RING domain dependent E3 ligase activity of Mdm2 has been shown to be essential for negative regulation of p53. The prevailing model has dubbed MdmX as an inhibitor of p53 transcriptional activity through direct binding of its N-terminal domain to p53. However, recent findings established an essential role of the RING domain of MdmX in p53 degradation in vitro and in vivo. Biochemically, Mdm2 on its own is a monoubiquitination E3 ligase, however, MdmX can convert Mdm2 into a polyubiquitination E3 ligase necessary for p53 proteasomal degradation in cells, through their RING-RING interaction. While Mdm2 is the catalytic component of Mdm2/MdmX E3 complex, MdmX is both the activating component and a substrate of the holoenzyme. Knock-in of RING mutant MdmX in mice causes p53-dependent embryonic lethality in a similar manner as knockout of MdmX whole gene. These recent advancements in the field assigned an essential role of the RING domain of MdmX in negative regulation of p53 in vivo, just like Mdm2 RING domain, through p53 degradation.
引用
收藏
页码:4225 / 4229
页数:5
相关论文
共 85 条
[11]   Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo [J].
Francoz, S ;
Froment, P ;
Bogaerts, S ;
De Clercq, S ;
Maetens, M ;
Doumont, G ;
Bellefroid, E ;
Marine, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (09) :3232-3237
[12]   TP53 and MTOR crosstalk to regulate cellular senescence [J].
Galluzzi, Lorenzo ;
Kepp, Oliver ;
Kroemer, Guido .
AGING-US, 2010, 2 (09) :535-537
[13]   Defective autophagy control by the p53 rheostat in cancer [J].
Galluzzi, Lorenzo ;
Morselli, Eugenia ;
Kepp, Oliver ;
Maiuri, Maria Chiara ;
Kroemer, Guido .
CELL CYCLE, 2010, 9 (02) :250-255
[14]   The relative contributions of the p53 and pRb pathways in oncogene induced melanocyte senescence [J].
Haferkamp, Sebastian ;
Tran, Sieu L. ;
Becker, Therese M. ;
Scurr, Lyndee L. ;
Kefford, Richard F. ;
Rizos, Helen .
AGING-US, 2009, 1 (06) :542-556
[15]   The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation [J].
Hashizume, R ;
Fukuda, M ;
Maeda, I ;
Nishikawa, H ;
Oyake, D ;
Yabuki, Y ;
Ogata, F ;
Ohta, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (18) :14537-14540
[16]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299
[17]   Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53 [J].
Heminger, Katherine ;
Markey, Michael ;
Mpagi, Meldrick ;
Berberich, Steven J. .
AGING-US, 2009, 1 (01) :89-108
[18]  
Hölzel M, 2010, ONCOTARGET, V1, P43
[19]   Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 [J].
Honda, R ;
Tanaka, H ;
Yasuda, H .
FEBS LETTERS, 1997, 420 (01) :25-27
[20]   Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3 [J].
Huang, Baoying ;
Vassilev, Lyubomir T. .
AGING-US, 2009, 1 (10) :845-854